Medifocus, Inc. (OTCQX: MDFZF) owns two fully developed technology platforms that the company believes can provide the design basis for the development of multiple cancer treatment systems. These technologies have comprehensive U.S. and international patent protection: The Endo-thermotherapy Platform, which is the base for the company’s FDA-approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH); and the Adaptive Phased Array (APA) Microwave Focusing Platform, which is the base for Medifocus’ APA 1000 Breast Cancer Treatment System. For more information, visit the company’s website at: www.medifocusinc.com